Browse by author
Lookup NU author(s): Professor Matthew CollinORCiD,
Dr Xiao WangORCiD,
Professor Anne Dickinson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Graft-versus-host disease (GvHD), a life-threatening complication of bone marrow transplantation, is initiated by donor T cells reacting to recipient dendritic cells (DC). GvHD can be controlled by attenuating donor T cells, but few strategies exist to target DC, particularly resident tissue DC, despite recent evidence of their importance. In this report, CMRF-44, a mouse monoclonal IgM reactive to human DC, is tested against human Langerhans cells (LC) in vitro. CMRF-44 antigen is expressed at low level on fresh LC but is up-regulated 40-60-fold during migration. CMRF-44 and complement kill more than 97% of migratory LC in vitro and inhibit allostimulation by LC up to 95%. In comparison, alemtuzumab, which binds CD52, reacts weakly with primary LC and fails to induce significant lysis with complement (less than 5%). These results highlight the potential of new therapeutic antibodies active against tissue DC to control graft-versus-host reactions. Copyright © 2005 by Lippincott Williams & Wilkins.
Author(s): Collin MP, Munster D, Clark G, Wang X-N, Dickinson AM, Hart DN
Publication type: Article
Publication status: Published
ISSN (print): 0041-1337
ISSN (electronic): 1534-6080
Publisher: Lippincott Williams & Wilkins
PubMed id: 15785380
Altmetrics provided by Altmetric